292 related articles for article (PubMed ID: 23095620)
1. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
2. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
5. Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
Sperlich A; Balmert A; Doll D; Bauer S; Franke F; Keller G; Wilhelm D; Mur A; Respondek M; Friess H; Nitsche U; Janssen KP
BMC Cancer; 2018 Oct; 18(1):998. PubMed ID: 30340556
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
8. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
11. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.
Isella C; Mellano A; Galimi F; Petti C; Capussotti L; De Simone M; Bertotti A; Medico E; Muratore A
Ann Surg; 2013 Jun; 257(6):1089-95. PubMed ID: 23665971
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
13. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
15. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
[TBL] [Abstract][Full Text] [Related]
17. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
18. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.
Berg M; Guriby M; Nordgård O; Nedrebø BS; Ahlquist TC; Smaaland R; Oltedal S; Søreide JA; Kørner H; Lothe RA; Søreide K
Mol Med; 2013 Sep; 19(1):286-93. PubMed ID: 23979710
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients.
Nordgård O; Oltedal S; Aasprong OG; Søreide JA; Søreide K; Tjensvoll K; Gilje B; Heikkilä R; Guriby M; Lothe RA; Smaaland R; Kørner H
Ann Surg Oncol; 2012 Nov; 19(12):3719-26. PubMed ID: 22752373
[TBL] [Abstract][Full Text] [Related]
20. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
